Annual reportSep 2026
Sep 2026 · Shareholders meeting 24 Aug - AGM scheduled for Sept 17, 2026; annual report sent and special resolution seeks Rs 100 crore Section 186 limit.
Source: Nse
Medistep Healthcare Ltd. (MEDISTEP)
SME CapPharma stocks · SME cap · NSE
Medistep Healthcare Ltd. operates in Services, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 01:54 pm ISTDetails
Quote21 Oct, 01:54 pm IST
Base fundamentals20 Oct 2026 · screener
Latest result01 Jun, 07:54 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
73BullishSMA20 +10.3% / mo · MACD + · near 52W low · sector +4.4pp vs Nifty 500 (3M)
Stock trend: 55
Sector RS: 100
Sector 3M: -1.7% vs Nifty 500 -6.1%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
MEDISTEPD candles · FIT view-7.6%Latest close ₹21.40 on 2026-10-19
Bar
+0.0%
RSI
54
MACD hist
0.02
52W pos
36%
2026-10-19O ₹21.40H ₹21.40L ₹21.40C ₹21.40Vol 3,000 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
MEDISTEPNifty PharmaNifty 500
- MEDISTEP
- +10.9%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- +16.5 pp
Chart stats
19 Oct 2026- From 52W high
- -59.6%
- 52W range position
- 13%
- ATR (14)
- 5.3%
- Volume vs 20D
- 0.22x
- Avg traded value
- ₹0 Cr
- 20D price channel
- ₹18.3 - ₹23.5
₹53
₹16.5 - ₹53
₹1.1
Latest completed session
20-session average
75.3% annualized volatility
Research snapshot
What the evidence says now
Investable fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend supports entry, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · UNDERVALUED69
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Pending data—
Revenue NDF · PAT NDF YoY
Technical
Bullish73
Price trend and sector-relative-strength timing.
Valuation
Legacy model+88.7%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence69
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Pending dataYoY comparison unavailable - result verdict pending data
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹35.8 Cr | NDF | +2.0% |
| EBITDA | ₹4.3 Cr | NDF | +7.3% |
| Operating margin | 11.9% | NDF | +59 bps |
| PAT | ₹3 Cr | NDF | +1.4% |
| PAT margin | 8.4% | NDF | -5 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 5.09
- P/B
- 0.80
- EV/EBITDA
- 4.29
- Market Cap
- 30.40Cr
Profitability
- ROE
- 21.70%
- ROCE
- 27.00%
- ROA
- 11.89%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 49.71%
- EPS 5Y
- 43.35%
- Revenue 3Y
- 24.00%
- EPS 3Y
- 24.00%
Balance Sheet
- Debt/Equity
- 0.14
- Interest Coverage
- 31.77×
- Altman Z
- 4.34
- Book Value
- 26.60
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 1/5
- OCF
- -19.48 Cr
- EPS TTM
- 4.21
Shareholding
- Promoter Hold
- 68.96%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 36%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 35.8+2.0% vs prev
Net Profit
₹ CrLatest: 3.0+1.3% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
NeutralTrend is undirectional — long-term trend unclear. RSI 54.
- SMA20 rising (~9.3% over last month) — short-term momentum positive.
- RSI(14) at 54 — sideways, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 29% off 52W high · 30% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
65
RS percentile
Stage 1 Base / Transition
1M return
+8.4%
3M return
+12.6%
6M return
-5.9%
1Y return
-
RS 1D
+4
RS 20D
+31
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is within 2.9% of the 30-week proxy.
- The 30-week proxy changed -3.5% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price above
200-DMA
price below
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
189 observations
19 Oct 2026Value 71.66+2.96%
RS vs Nifty 50072
Valuation & peers
U-Score 69 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 69 · legacy U-Score band UNDERVALUED · valuation evidence and comparable companies
Deep Value
Fundamental score breakdown
U band · UNDERVALUEDValuation30/30
Growth18/25
Quality14/20
Balance Sheet12/15
Cash Flow0/10
Piotroski
6/9 (+3)
Penalties
-8
Raw sum
69
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
69/100 · legacy band UNDERVALUED
Positive drivers
- Fair-value margin of safety is positive at 88.7%.
- Valuation contributes 30/30 to the score.
- Balance sheet contributes 12/15 to the score.
Main drags
- Penalty bucket subtracts 8 points.
- Cash flow is weaker at 0/10; verify the latest quarterly trend.
- Quality is weaker at 14/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
5.1
PB
0.8
EV/EBITDA
4.3
ROE
21.7%
ROCE
27.0%
FCF Yield
—
Debt/Equity
0.1
MoS
+88.7%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
69
Previous: 69
Legacy U-Score band
UNDERVALUED
Previous: UNDERVALUED
Margin of safety
+88.7%
Previous: +88.7%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
69
69
69
69
69
69
69
69
69
69
69
69
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹50.2
+57.4% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹189.45
+88.7% MoS
PEG
0.14
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
QMSMEDI
SME
QMS Medical Allied Services Ltd.
Healthcare Services
match 147
32
33.4
10.4%
+29%
WATCHLIST
DHTL
SME
Docmode Health Technologies Ltd.
Healthcare Services
match 128
13
—
-1.6%
—
OVERVALUED
MANGALAM
Small
Mangalam Drugs And Organics Limited
Healthcare Services
match 123
2
—
-35.2%
—
OVERVALUED
MAXHEALTH
Large
Max Healthcare Institute Limited
Healthcare Services
match 123
35
67.5
12.7%
-497%
WATCHLIST
VIVIMEDLAB
Small
Vivimed Labs Limited
Healthcare Services
match 123
13
—
—
—
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Medistep Healthcare Ltd. operates in Services, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
69Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 59th percentile of the scored universe and 46th percentile within Pharma. Main check: cash conversion is weak at 28/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
0 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
59th percentile
overall median 67 · Pharma: 46th pctile, median 70 · SME: 77th pctile, median 64
Evidence depth
Financial-only
0 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
86
strong · holding, pledge, alignment
Cash flow
28
weak · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
90
strong · capital discipline
Results
63
acceptable · quarterly consistency
Trust positives
- ▸Promoter holding is 69%.
- ▸Promoter pledge is zero.
- ▸ROCE is 27.2%.
- ▸OPM spread across recent quarters is 1.2%.
Trust risks
- ▸Operating cash flow is negative at ₹-19 Cr.
- ▸Only 1 years of positive FCF.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Medistep Healthcare Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Nse
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.